Provence Technologies Group, a Marseille, France-based specialist fine chemistry research group, acquired Synprosis, an Aix-en-Provence, France-based company specialized in the chemical synthesis of peptides and proteins for therapeutic use.
The Group’s new entity has rebranded as Provepep.
The financial terms of the transaction were not disclosed.
Founded by Jean-Pierre Salles, who will remain in the Provepep executive management team, Synprosis has a ten-year history of producing active principles in the field of vaccines under development (for malaria, cancer, and allergies, etc.), as well as in other therapeutic fields (for neurogenerative diseases and the treatment of pain).
For Provence Technologies Group, the acquisition is consistent with the management team’s strategic objective to strengthen its core business of therapeutic chemistry and the deal opens up new development opportunities for the Provence Technologies Group in the area of biologically active pharmaceuticals.
Led by Michel Feraud, chairman and CEO, Provence Technologies Group is an independent company offering R&D services to the pharmaceutical, biopharmaceutical, agrochemical and cosmetic industries in the area of fine chemistry, including research into synthesis pathways, synthesis of organic compounds, chemical development and process optimisation. It also provides services in the development and validation of analytical methods.
Founded in 1998, the company generated revenues of €2.5m in 2013 (€6m for the Group).
FinSMEs
03/06/2014